Bilateral agreements with Australia and Korea include rules favoring brand-name drug companies over policymakers tasked with controlling costs.

The U.S. Trade Representative uses its annual report on countries that 'deny fair and equitable market access' to firms that rely on intellectual property protection to attack evidence based pricing of pharmaceuticals. The report singles out practices shared by foreign country governments and US state governments that purchase medicines.